Early heart failure with preserved ejection fraction (HFpEF) is a frequent disease, but its diagnosis is difficult and relies mostly on the evidence of left ventricular filling pressure (LVFP) elevation during exercise. Several reports have suggested that natriuretic peptides plasma levels reflect exercise-induced increase in LVFP, but they still have significant limitations. In this context, any new laboratory biomarker that can accurately reflect LVFP elevation during exercise is desirable. Recently, cardiotrophin-1, soluble endoglin, ST2, growth differentiation factor 15, galectin-3, and other new laboratory markers associated with LVFP have emerged. However, the current data on the relationship of these biomarkers and diastolic dysfunction are limited to resting conditions. Therefore, their secretion deserves to be tested under the exercise to determine their potential role in making a diagnosis of early HFpEF.

Department of Cardiovascular Diseases St Anne's Hospital ICRC 65691 Brno Czech Republic ; Department of Cardiovascular Diseases Masaryk University Brno Czech Republic

ICRC Brno Czech Republic ; Department of Biochemistry Faculty of Medicine Masaryk University 62500 Brno Czech Republic

See more in PubMed

Bhatia R. S., Tu J. V., Lee D. S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. The New England Journal of Medicine. 2006;355(3):260–269. doi: 10.1056/nejmoa051530. PubMed DOI

Owan T. E., Hodge D. O., Herges R. M., Jacobsen S. J., Roger V. L., Redfield M. M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England Journal of Medicine. 2006;355(3):251–259. doi: 10.1056/nejmoa052256. PubMed DOI

Paulus W. J., Tschöpe C., Sanderson J. E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal. 2007;28(20):2539–2550. doi: 10.1093/eurheartj/ehm037. PubMed DOI

McMurray J. J. V., Adamopoulos S., Anker S. D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2012;33:1787–1847. PubMed

Holland D. J., Prasad S. B., Marwick T. H. Contribution of exercise echocardiography to the diagnosis of heart failure with preserved ejection fraction (HFpEF) Heart. 2010;96(13):1024–1028. doi: 10.1136/hrt.2009.183947. PubMed DOI

Meluzín J., Sitar J., Křístek J., et al. The role of exercise echocardiography in the diagnostics of heart failure with normal left ventricular ejection fraction. European Journal of Echocardiography. 2011;12(8):591–602. doi: 10.1093/ejechocard/jer082. PubMed DOI

Meluzin J., Hude P., Leinveber P., et al. High prevalence of exercise-induced heart failure with normal ejection fraction in post-heart transplant patients. Biomedical Papers. 2014;158(2):295–302. doi: 10.5507/bp.2013.095. PubMed DOI

Borlaug B. A., Nishimura R. A., Sorajja P., Lam C. S. P., Redfield M. M. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circulation: Heart Failure. 2010;3(5):588–595. doi: 10.1161/circheartfailure.109.930701. PubMed DOI PMC

Burgess M. I., Jenkins C., Sharman J. E., Marwick T. H. Diastolic stress echocardiography: hemodynamic validation and clinical significance of estimation of left ventricular filling pressure with exercise. Journal of the American College of Cardiology. 2006;47(9):1891–1900. doi: 10.1016/j.jacc.2006.02.042. PubMed DOI

Talreja D. R., Nishimura R. A., Oh J. K. Estimation of left ventricular filling pressure with exercise by Doppler echocardiography in patients with normal systolic function: a simultaneous echocardiographic-cardiac catheterization study. Journal of the American Society of Echocardiography. 2007;20(5):477–479. doi: 10.1016/j.echo.2006.10.005. PubMed DOI

Dalsgaard M., Kjaergaard J., Pecini R., et al. Left ventricular filling pressure estimation at rest and during exercise in patients with severe aortic valve stenosis: comparison of echocardiographic and invasive measurements. Journal of the American Society of Echocardiography. 2009;22(4):343–349. doi: 10.1016/j.echo.2009.01.007. PubMed DOI

Maeder M. T., Thompson B. R., Brunner-La Rocca H.-P., Kaye D. M. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. Journal of the American College of Cardiology. 2010;56(11):855–863. doi: 10.1016/j.jacc.2010.04.040. PubMed DOI

Meluzin J., Hude P., Krejci J., et al. Noninvasive prediction of the exercise-induced elevation in left ventricular filling pressure in post-heart transplant patients with normal left ventricular ejection fraction. Experimental & Clinical Cardiology. 2013;18(2):63–72. PubMed PMC

Andersen M. J., Ersbøll M., Gustafsson F., et al. Exercise-induced changes in left ventricular filling pressure after myocardial infarction assessed with simultaneous right heart catheterization and Doppler echocardiography. International Journal of Cardiology. 2013;168(3):2803–2810. doi: 10.1016/j.ijcard.2013.03.122. PubMed DOI

Bansal M., Marwick T. H. Natriuretic peptides and filling pressure at rest and stress. Heart Failure Clinics. 2008;4(1):71–86. doi: 10.1016/j.hfc.2007.10.003. PubMed DOI

Potocki M., Breidthardt T., Reichlin T., et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. Journal of Internal Medicine. 2010;267(1):119–129. doi: 10.1111/j.1365-2796.2009.02135.x. PubMed DOI

Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90(1):195–203. doi: 10.1161/01.CIR.90.1.195. PubMed DOI

Keller N., Larsen J., Sykulski R., Storm T., Thamsborg G. Atrial natriuretic factor during exercise in patients with congestive heart failure. Acta Endocrinologica. 1988;118(2):168–172. PubMed

Matsubara H., Nishikawa M., Umeda Y., et al. The role of atrial pressure in secreting atrial natriuretic polypeptides. The American Heart Journal. 1987;113(6):1457–1463. doi: 10.1016/0002-8703(87)90662-4. PubMed DOI

Walsh K. P., Williams T. D. M., Spiteri C., Pitts E., Lightman S. L., Sutton R. Role of atrial pressure and rate in release of atrial natriuretic peptide. The American Journal of Physiology—Regulatory Integrative and Comparative Physiology. 1988;254:R607–R610. PubMed

Matsumoto A., Hirata Y., Momomura S.-I., et al. Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricuiar dysfunction. American Heart Journal. 1995;129(1):139–145. doi: 10.1016/0002-8703(95)90054-3. PubMed DOI

Adams K. F., Jr., Mathur V. S., Gheorghiade M. B-Type natriuretic peptide: from bench to bedside. The American Heart Journal. 2003;145(2):S34–S46. doi: 10.1067/mhj.2003.152. PubMed DOI

Ikeda N., Yasu T., Nishikimi T., et al. N-terminal pro-atrial natriuretic peptide and exercise prescription in patients with myocardial infarction. Regulatory Peptides. 2007;141(1–3):154–158. doi: 10.1016/j.regpep.2006.12.024. PubMed DOI

Onuoha G. N., Nicholls D. P., Patterson A., Beringer T. Neuropeptide secretion in exercise. Neuropeptides. 1998;32(4):319–325. doi: 10.1016/S0143-4179(98)90054-3. PubMed DOI

Abhayaratna W. P., Marwick T. H., Becker N. G., Jeffery I. M., McGill D. A., Smith W. T. Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. American Heart Journal. 2006;152(5):941–948. doi: 10.1016/j.ahj.2006.05.007. PubMed DOI

Fradley M. G., Larson M. G., Cheng S., et al. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study) The AmericanJournal of Cardiology. 2011;108(9):1341–1345. doi: 10.1016/j.amjcard.2011.06.057. PubMed DOI PMC

Qi W., Mathisen P., Kjekshus J., et al. Natriuretic peptides in patients with aortic stenosis. American Heart Journal. 2001;142(4):725–732. doi: 10.1067/mhj.2001.117131. PubMed DOI

Rogers R. K., Stoddard G. J., Greene T., et al. Usefulness of adjusting for clinical covariates to improve the ability of B-type natriuretic peptide to distinguish cardiac from noncardiac dyspea. The American Journal of Cardiology. 2009;104(5):689–694. doi: 10.1016/j.amjcard.2009.04.043. PubMed DOI

Galasko G. I. W., Lahiri A., Barnes S. C., Collinson P., Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? European Heart Journal. 2005;26(21):2269–2276. doi: 10.1093/eurheartj/ehi410. PubMed DOI

O'Hanlon R., O'Shea P., Ledwidge M., et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. Journal of Cardiac Failure. 2007;13(1):50–55. doi: 10.1016/j.cardfail.2006.09.003. PubMed DOI

Mottram P. M., Leano R., Marwick T. H. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. The American Journal of Cardiology. 2003;92(12):1434–1438. doi: 10.1016/j.amjcard.2003.08.053. PubMed DOI

Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002;105(5):595–601. doi: 10.1161/hc0502.103010. PubMed DOI

Tschöpe C., Kašner M., Westermann D., Gaub R., Poller W. C., Schultheiss H.-P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. European Heart Journal. 2005;26(21):2277–2284. doi: 10.1093/eurheartj/ehi406. PubMed DOI

Watanabe S., Shite J., Takaoka H., et al. Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure. European Heart Journal. 2006;27(7):832–838. doi: 10.1093/eurheartj/ehi772. PubMed DOI

Kasner M., Gaub R., Westermann D., et al. Simultaneous estimation of NT-proBNP on top to mitral flow Doppler echocardiography as an accurate strategy to diagnose diastolic dysfunction in HFNEF. International Journal of Cardiology. 2011;149(1):23–29. doi: 10.1016/j.ijcard.2009.11.035. PubMed DOI

Dahlström U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? European Journal of Heart Failure. 2004;6(3):281–287. doi: 10.1016/j.ejheart.2004.01.005. PubMed DOI

Joung B., Ha J.-W., Ko Y. G., et al. Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function? American Heart Journal. 2005;150(6):1213–1219. doi: 10.1016/j.ahj.2005.01.014. PubMed DOI

Redfield M. M., Rodeheffer R. J., Jacobsen S. J., Mahoney D. W., Bailey K. R., Burnett J. C., Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation. 2004;109(25):3176–3181. doi: 10.1161/01.CIR.0000130845.38133.8F. PubMed DOI

McCullough P. A., Nowak R. M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106(4):416–422. doi: 10.1161/01.cir.0000025242.79963.4c. PubMed DOI

Pemberton C. J., Raudsepp S. D., Yandle T. G., Cameron V. A., Richards A. M. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovascular Research. 2005;68(1):109–117. doi: 10.1016/j.cardiores.2005.05.014. PubMed DOI

Takimoto Y., Aoyama T., Iwanaga Y., et al. Increased expression of cardiotrophin-1 during ventricular remodeling in hypertensive rats. The American Journal of Physiology—Heart and Circulatory Physiology. 2002;282(3):H896–H901. PubMed

López B., González A., Querejeta R., Barba J., Díez J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. Journal of Hypertension. 2009;27(2):418–424. doi: 10.1097/hjh.0b013e32831ac981. PubMed DOI

López B., González A., Querejeta R., Larman M., Rábago G., Díez J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension. 2014;63(3):483–489. doi: 10.1161/hypertensionaha.113.02654. PubMed DOI

Celik A., Sahin S., Koc F., et al. Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Medical Science Monitor. 2012;18(1):CR25–CR31. PubMed PMC

Kapur N. K., Heffernan K. S., Yunis A. A., et al. Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. The American Journal of Cardiology. 2010;106(12):1770–1776. doi: 10.1016/j.amjcard.2010.08.018. PubMed DOI PMC

Fitzgibbons T. P., Paolino J., Dagorn J. C., Meyer T. E. Usefulness of pancreatitis-associated protein, a novel biomarker, to predict severity of disease in ambulatory patients with heart failure. The American Journal of Cardiology. 2014;113(1):123–126. doi: 10.1016/j.amjcard.2013.09.026. PubMed DOI

Shah R. V., Januzzi J. L., Jr. ST2: a novel remodeling biomarker in acute and chronic heart failure. Current Heart Failure Reports. 2010;7(1):9–14. doi: 10.1007/s11897-010-0005-9. PubMed DOI

Bartunek J., Delrue L., van Durme F., et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. Journal of the American College of Cardiology. 2008;52(25):2166–2174. doi: 10.1016/j.jacc.2008.09.027. PubMed DOI PMC

Wang Y.-Ch., Yu C.-Ch., Chiu F.-Ch., et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. Journal of Cardiac Failure. 2013;19(3):163–168. doi: 10.1016/j.cardfail.2013.01.010. PubMed DOI

Santhanakrishnan R., Chong J. P. C., Ng T. P., et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. European Journal of Heart Failure. 2012;14(12):1338–1347. doi: 10.1093/eurjhf/hfs130. PubMed DOI

Stahrenberg R., Edelmann F., Mende M., et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. European Journal of Heart Failure. 2010;12(12):1309–1316. doi: 10.1093/eurjhf/hfq151. PubMed DOI PMC

De Boer R. A., Yu L., Van Veldhuisen D. J. Galectin-3 in cardiac remodeling and heart failure. Current Heart Failure Reports. 2010;7(1):1–8. doi: 10.1007/s11897-010-0004-x. PubMed DOI PMC

Carrasco-Sánchez F. J., Aramburu-Bodas O., Salamanca-Bautista P., et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. International Journal of Cardiology. 2013;169(3):177–182. doi: 10.1016/j.ijcard.2013.08.081. PubMed DOI

de Boer R. A., Lok D. J. A., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine. 2011;43(1):60–68. doi: 10.3109/07853890.2010.538080. PubMed DOI PMC

Ho J. E., Liu C., Lyass A., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. Journal of the American College of Cardiology. 2012;60(14):1249–1256. doi: 10.1016/j.jacc.2012.04.053. PubMed DOI PMC

Shah R. V., Chen-Tournoux A. A., Picard M. H., van Kimmenade R. R. J., Januzzi J. L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure. 2010;12(8):826–832. doi: 10.1093/eurjhf/hfq091. PubMed DOI PMC

Andersen M. J., Ersbøll M., Bro-Jeppesen J., et al. Relationships between biomarkers and left ventricular filling pressures at rest and during exercise in patients after myocardial infarction. Journal of Cardiac Failure. 2014;20(12):959–967. doi: 10.1016/j.cardfail.2014.09.012. PubMed DOI

Hung C.-L., Hung T.-C., Liu C.-C., et al. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. The American Journal of Cardiology. 2012;110(7):993–1000. doi: 10.1016/j.amjcard.2012.05.030. PubMed DOI

Limongelli G., Calabrò P., Maddaloni V., et al. Cardiotrophin-1 and TNF-α circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. Cytokine. 2010;50(3):245–247. doi: 10.1016/j.cyto.2009.12.007. PubMed DOI

Huang W.-S., Lee M.-S., Perng H.-W., Yang S.-P., Kuo S.-W., Chang H.-D. Circulating brain natriuretic peptide values in healthy men before and after exercise. Metabolism: Clinical and Experimental. 2002;51(11):1423–1426. doi: 10.1053/meta.2002.35194. PubMed DOI

Kohno M., Horio T., Yokokawa K., Akioka K., Ikeda M., Takeda T. Pulmonary arterial brain natriuretic peptide concentration and cardiopulmonary hemodynamics during exercise in patients with essential hypertension. Metabolism: Clinical and Experimental. 1992;41(12):1273–1275. doi: 10.1016/0026-0495(92)90095-R. PubMed DOI

Mottram P. M., Haluska B. A., Marwick T. H. Response of B-type natriuretic peptide to exercise in hypertensive patients with suspected diastolic heart failure: correlation with cardiac function, hemodynamics, and workload. The American Heart Journal. 2004;148(2):365–370. doi: 10.1016/j.ahj.2004.02.012. PubMed DOI

Collier P., Watson C. J., Voon V., et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? European Journal of Heart Failure. 2011;13(10):1087–1095. doi: 10.1093/eurjhf/hfr079. PubMed DOI

van Kimmenade R. R. J., Januzzi J. L., Jr. Emerging biomarkers in heart failure. Clinical Chemistry. 2012;58(1):127–138. doi: 10.1373/clinchem.2011.165720. PubMed DOI

Baker B. J., Wu W. C. L., Winters C. J., et al. Exercise increases the circulating concentration of the N-terminus of the atrial natriuretic factor prohormone in normal individuals. The American Heart Journal. 1991;122(5):1395–1402. doi: 10.1016/0002-8703(91)90583-4. PubMed DOI

Saito Y., Nakao K., Sugawara A., et al. Atrial natriuretic polypeptide during exercise in healthy man. Acta Endocrinologica. 1987;116(1):59–65. PubMed

Follenius M., Brandenberger G. Increase in atrial natriuretic peptide in response to physical exercise. European Journal of Applied Physiology and Occupational Physiology. 1988;57(2):159–162. doi: 10.1007/BF00640656. PubMed DOI

Somers V. K., Anderson J. V., Conway J., Sleight P., Bloom S. R. Atrial natriuretic peptide is released by dynamic exercise in man. Hormone and Metabolic Research. 1986;18(12):871–872. doi: 10.1055/s-2007-1012460. PubMed DOI

Petzl D. H., Hartter E., Osterode W., Böhm H., Woloszczuk W. Atrial natriuretic peptide release due to physical exercise in healthy persons and in cardiac patients. Klinische Wochenschrift. 1987;65(4):194–196. doi: 10.1007/BF01728234. PubMed DOI

Nishikimi T., Morimoto A., Ishikawa K., et al. Different secretion patterns of adrenomedullin, brain natriuretic peptide, and atrial natriuretic peptide during exercise in hypertensive and normotensive subjects. Clinical and Experimental Hypertension. 1997;19(4):503–518. doi: 10.3109/10641969709084511. PubMed DOI

Tanaka M., Ishizaka Y., Ishiyama Y., et al. Exercise-induced secretion of brain natriuretic peptide in essential hypertension and normal subjects. Hypertension Research—Clinical and Experimental. 1995;18(2):159–166. doi: 10.1291/hypres.18.159. PubMed DOI

Raine A. E. G., Erne P., Bürgisser E., et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. The New England Journal of Medicine. 1986;315(9):533–537. doi: 10.1056/nejm198608283150901. PubMed DOI

Steele I. C., McDowell G., Moore A., et al. Responses of atrial natriuretic peptide and brain natriuretic peptide to exercise in patients with chronic heart failure and normal control subjects. European Journal of Clinical Investigation. 1997;27(4):270–276. doi: 10.1046/j.1365-2362.1997.1070653.x. PubMed DOI

Wijbenga J. A. M., Balk A. H. M. M., Boomsma F., Man A. J., Hall C. Cardiac peptides differ in their response to exercise. Implications for patients with heart failure in clinical practice. European Heart Journal. 1999;20(19):1424–1428. doi: 10.1053/euhj.1999.1630. PubMed DOI

Tschöpe C., Kasner M., Westermann D., et al. Elevated NT-ProBNP levels in patients with increased left ventricular filling pressure during exercise despite preserved systolic function. Journal of Cardiac Failure. 2005;11(5):S28–S33. doi: 10.1016/j.cardfail.2005.04.013. PubMed DOI

Fukuta H., Little W. C. Elevated left ventricular filling pressure after maximal exercise predicts increased plasma B-type natriuretic peptide levels in patients with impaired relaxation pattern of diastolic filling. Journal of the American Society of Echocardiography. 2007;20(7):832–837. doi: 10.1016/j.echo.2007.01.004. PubMed DOI